犬インフルエンザ・ワクチンの世界市場

犬インフルエンザ・ワクチンの世界市場は2030年までに23億米ドルに達する見込み

2024年に18億米ドルと推定される犬インフルエンザ・ワクチンの世界市場は、分析期間2024-2030年にCAGR 4.3%で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである組み換えワクチンは、CAGR 4.9%を記録し、分析期間終了時には14億米ドルに達すると予測されます。不活化ワクチン分野の成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は4億7,730万米ドルと推定、中国はCAGR 8.0％で成長予測

米国の犬インフルエンザ・ワクチン市場は、2024年には4億7,730万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,740万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.4%と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の犬インフルエンザ・ワクチン市場- 主要動向と促進要因のまとめ

なぜ犬インフルエンザ・ワクチンは予防獣医療の重要な要素になりつつあるのか？

犬インフルエンザ・ワクチンは、特に犬小屋、シェルター、寄宿施設、動物病院において、犬の間で伝染性の高い呼吸器疾患の蔓延を抑えるために不可欠なツールとして脚光を浴びています。主にH3N8およびH3N2ウイルス株によって引き起こされる犬インフルエンザは、急性の呼吸器疾患の発生と関連しており、ペットの健康と地域の動物管理にとって重大な脅威となっています。永続的な自然免疫はなく、エアロゾル化した飛沫や汚染された表面を介してウイルスが急速に伝播するため、ワクチン接種が依然として予防と集団レベルの疾病管理の最も効果的な形態です。

ペットの飼育が世界的に増加し、家庭、グルーミングセンター、デイケア施設間の移動が増加するにつれ、獣医師は定期的なワクチン接種を推奨するようになってきています。犬インフルエンザは現在のところヒトには感染しませんが、人獣共通感染症のリスクに対する認識が高まっていることも、飼い主が責任あるペットケアの一環として包括的な予防接種戦略を採用することに影響しています。

株特異的製剤と混合ワクチンは、どのように製品の普及と獣医師のコンプライアンスを高めているか？

メーカーは一価ワクチン（H3N8またはH3N2）と二価ワクチンの両方を提供しており、流通している株に対してより幅広い防御を提供しています。両方のウイルス型が共存し、二重株のアウトブレイクの可能性があるため、多くの市場で二価製剤が標準になりつつあります。これらのワクチンは通常、2回接種の後、年1回のブースター接種を行うことで、リスクの高い犬を年間を通して確実に予防することができます。

さらに、犬インフルエンザ予防をボルデテラ、パラインフルエンザ、ジステンパーなどの他の中核抗原と組み合わせた多価混合ワクチンに組み込むことで、飼い主のコンプライアンスを向上させ、獣医診療における物流の障壁を軽減しています。これらの組み合わせ製剤は、包括的な呼吸器保護を提供しながら投与を合理化し、保護医療や定期的なウェルネス・プロトコールにおいて特に魅力的です。

犬インフルエンザ・ワクチンの需要が高まっている地域と、市場拡大を牽引しているペット飼育動向は？

北米は犬インフルエンザ・ワクチンの最大市場であり、その原動力となっているのは、強固なペットケアのインフラ、ワクチン接種に対する高い意識、予防ケアの基準を形成した過去の地域的な大流行です。特に米国は、組織化されたペットサービスの普及と州または施設レベルでのワクチン義務化により、ワクチン普及でリードしています。特に英国、ドイツ、フランスでは、ペット旅行に関する規制や犬舎の基準により、先制ワクチン接種が奨励されています。

中国、日本、韓国などの国々では、都市化、可処分所得の増加、ペット飼育の拡大がコンパニオンアニマルワクチンの需要を牽引しており、アジア太平洋は加速度的な成長を目の当たりにしています。これらの地域では、動物病院へのアクセスが向上し、欧米の予防医療の影響力が高まるにつれ、ペットの飼育がより体系化されつつあります。ペット保険やウェルネスプランの役割の増大も、インフルエンザを含む定期的な予防接種の動機付けとなっています。

犬インフルエンザ・ワクチン市場の世界的成長の原動力は？

世界の犬インフルエンザ・ワクチン市場は、疾病サーベイランスの強化、獣医による予防医療導入の増加、コンパニオンアニマルの健康に対する経済的価値の高まりにより拡大しています。疾病の発生、メディア報道、専門家協会のガイドラインにより、公衆および獣医療部門は予防接種を重視する傾向が強まっています。さらに、獣医診療所の統合、企業獣医ネットワークの拡大、ペット預かり所やデイケアサービスの拡大により、業務プロトコルの一部としてワクチン遵守が制度化されつつあります。

コールドチェーンロジスティクスと世界の流通への投資と並んで、ワクチン技術、株ターゲティング、送達メカニズムの進歩が、市場の拡張性を支えています。コンパニオンアニマルヘルスがより医療化され、予防に重点を置くようになるにつれ、決定的な疑問が浮かび上がってきます。犬インフルエンザ・ワクチンメーカーは、地域のリスクプロファイルに対応し、ますます移動し都市化する世界のペット人口における一貫した予防を確保しながら、認知度、アクセス、多価製品のイノベーションを拡大することができるでしょうか？

セグメント

ワクチンタイプ（組み換えワクチン、不活化ワクチン、その他のワクチンタイプ）、ウイルスタイプ（H3N8ウイルス、H3N2ウイルス）、販売チャネル（公共、民間）

調査対象企業の例（注目の44社）

• Bayer Animal Health
• Bimeda Animal Health
• Boehringer Ingelheim Animal Health
• Ceva Sante Animale
• Chengdu Qianhong Bio-pharma Co.
• China Animal Husbandry Industry Co.
• China National Biotec Group
• Covetrus
• CSL Limited
• Elanco Animal Health
• Heska Corporation
• HIPRA
• IDEXX Laboratories
• Intervet Inc.（Merck Animal Health）
• Jinyu Bio-Technology Co., Ltd.
• Kyoritsu Seiyaku Corporation
• Laboratorios Karizoo
• Lohmann Animal Health
• Merial（now part of Boehringer Ingelheim）
• Neogen Corporation

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフエコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Canine influenza Vaccines Market to Reach US$2.3 Billion by 2030

The global market for Canine Influenza Vaccines estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$477.3 Million While China is Forecast to Grow at 8.0% CAGR

The Canine influenza Vaccines market in the U.S. is estimated at US$477.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.4 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Canine Influenza Vaccines Market - Key Trends & Drivers Summarized

Why Are Canine Influenza Vaccines Becoming a Critical Component of Preventive Veterinary Care?

Canine influenza vaccines are gaining prominence as essential tools in controlling the spread of highly contagious respiratory diseases among dogs-particularly in kennels, shelters, boarding facilities, and veterinary clinics. Canine influenza, caused primarily by the H3N8 and H3N2 virus strains, is associated with outbreaks of acute respiratory illness and presents a significant threat to pet health and community animal management. With no lasting natural immunity and rapid viral transmission through aerosolized droplets or contaminated surfaces, vaccination remains the most effective form of prevention and population-level disease control.

As pet ownership increases globally and mobility between households, grooming centers, and daycare facilities rises, veterinarians are increasingly recommending routine vaccination-especially for dogs in high-density environments or with frequent social exposure. Rising awareness of zoonotic risks, even though canine influenza does not currently transmit to humans, is also influencing owners to adopt comprehensive immunization strategies as part of responsible pet care.

How Are Strain-Specific Formulations and Combination Vaccines Enhancing Product Adoption and Veterinary Compliance?

Manufacturers are offering both monovalent (H3N8 or H3N2) and bivalent vaccines that provide broader protection against circulating strains. Bivalent formulations are becoming the standard in many markets due to the co-circulation of both virus types and the potential for dual-strain outbreaks. These vaccines are typically administered in a two-dose series followed by annual boosters, ensuring year-round protection in high-risk dogs.

In addition, the integration of canine influenza protection into multivalent combination vaccines-bundled with other core antigens such as bordetella, parainfluenza, and distemper-is improving owner compliance and reducing logistical barriers in veterinary practice. These combination formulations are particularly attractive in shelter medicine and routine wellness protocols, streamlining administration while delivering comprehensive respiratory protection.

Where Is Demand for Canine Influenza Vaccines Rising and Which Pet Ownership Trends Are Driving Market Expansion?

North America is the largest market for canine influenza vaccines, driven by robust pet care infrastructure, high levels of vaccination awareness, and past regional outbreaks that have shaped preventive care standards. The United States, in particular, leads in vaccine adoption due to the prevalence of organized pet services and state or facility-level vaccine mandates. Europe follows with steady growth, especially in the U.K., Germany, and France, where pet travel regulations and kennel standards encourage preemptive vaccination.

Asia-Pacific is witnessing accelerated growth, with urbanization, rising disposable income, and expanding pet ownership in countries such as China, Japan, and South Korea driving demand for companion animal vaccines. Pet adoption in these regions is becoming more structured, with greater access to veterinary care and growing influence of Western preventive care practices. The increasing role of pet insurance and wellness plans is also incentivizing routine immunization, including influenza coverage.

What Is Fueling the Global Growth of the Canine Influenza Vaccines Market?

The global canine influenza vaccines market is expanding due to heightened disease surveillance, increasing veterinary preventive care adoption, and the growing economic value placed on companion animal health. Outbreak events, media coverage, and professional association guidelines have strengthened public and veterinary sector emphasis on immunization. Additionally, the consolidation of veterinary practices, growth of corporate vet networks, and expansion of pet boarding and daycare services are institutionalizing vaccine compliance as part of operational protocols.

Advances in vaccine technology, strain targeting, and delivery mechanisms-alongside investments in cold chain logistics and global distribution-are supporting market scalability. As companion animal health becomes more medicalized and prevention-focused, a defining question emerges: Can canine influenza vaccine manufacturers scale awareness, access, and multivalent product innovation-while addressing regional risk profiles and ensuring consistent protection in an increasingly mobile and urbanized global pet population?

SCOPE OF STUDY:

The report analyzes the Canine influenza Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Recombinant Vaccines, Inactivated Vaccines, Other Vaccine Types); Virus Type (H3N8 virus, H3N2 virus); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Bayer Animal Health
• Bimeda Animal Health
• Boehringer Ingelheim Animal Health
• Ceva Sante Animale
• Chengdu Qianhong Bio-pharma Co.
• China Animal Husbandry Industry Co.
• China National Biotec Group
• Covetrus
• CSL Limited
• Elanco Animal Health
• Heska Corporation
• HIPRA
• IDEXX Laboratories
• Intervet Inc. (Merck Animal Health)
• Jinyu Bio-Technology Co., Ltd.
• Kyoritsu Seiyaku Corporation
• Laboratorios Karizoo
• Lohmann Animal Health
• Merial (now part of Boehringer Ingelheim)
• Neogen Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Canine influenza Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Pet Ownership and Zoonotic Disease Awareness Fuel Market for Canine Influenza Vaccines
  • Outbreaks in Kennels, Shelters, and Daycare Facilities Drive Mass Vaccination Demand
  • Combination Vaccines Covering H3N8 and H3N2 Strains Enhance Product Appeal and Coverage Scope
  • Veterinary Associations Recommend Routine Influenza Immunization in High-Risk Canine Populations
  • Pet Insurance and Preventive Care Packages Support Vaccine Uptake in Companion Animal Health Plans
  • Emerging Canine Flu Hotspots Spur Regulatory and Import Controls Influencing Regional Demand
  • Expansion of Veterinary Clinics and Mobile Vaccination Units Improves Access in Urban and Rural Areas
  • Growing Demand for Injectable and Intranasal Formulations Offers Administration Flexibility
  • Manufacturer Focus on Supply Chain Resilience and Cold Chain Logistics Ensures Market Readiness
  • Canine Wellness Programs and Subscription Vet Services Integrate Flu Shots as Preventive Standards
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Canine influenza Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Canine influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Canine influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Canine influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for H3N8 virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for H3N8 virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for H3N8 virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for H3N2 virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for H3N2 virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for H3N2 virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• JAPAN
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• CHINA
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• EUROPE
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Canine influenza Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Canine influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• FRANCE
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• GERMANY
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Canine influenza Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• INDIA
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Canine influenza Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Canine influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Canine influenza Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Canine influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• AFRICA
  • Canine influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Canine influenza Vaccines by Vaccine Type - Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Canine influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines, Inactivated Vaccines and Other Vaccine Types for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Canine influenza Vaccines by Virus Type - H3N8 virus and H3N2 virus Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Canine influenza Vaccines by Virus Type - Percentage Breakdown of Value Sales for H3N8 virus and H3N2 virus for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Canine influenza Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Canine influenza Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Canine influenza Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030

IV. COMPETITION